Navigation Links
Cancer Biomarker Market (Global & USA) to 2018 - Trends and Pipeline Analysis
Date:8/7/2014

DALLAS, Aug. 7, 2014 /PRNewswire-iReach/ -- Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis) is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment.

(Photo - http://photos.prnewswire.com/prnh/20140807/134312)  

Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets.

One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine.

Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes.

Purchase Report @ http://www.reportsnreports.com/purchase.aspx?name=291987.

This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified.

In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics.

Table of Contents

1.0 Executive Summary 13

2.0 Global Burden of Cancer 20

3.0 Oncogenic Biomarkers – An Overview 54

4.0 Biomarker Validation 73
4.1 Introduction 73
4.2 Phases of Biomarker Validation 73
4.3 Biomarker Validation and Clinical Trials 75

5.0 Current and Prospective Oncogenic Biomarkers 77

6.0 Cancer Biomarker Test Market Analysis 2013-2018 101

7.0 Oncology Biomarker Market Main Industry Players 115
7.1 23andMe 115
7.2 Affymetrix 116
7.3 Ambry Genetics 118
7.4 Astex Pharmaceuticals 119
7.5 Atossa Genetics 121
7.6 CuraGen 122
7.7 Celera Corporation (Quest Diagnostics) 122
7.8 Celldex Therapeutics 122
7.9 deCode Genetics (Amgen) 124
7.10 Foundation Medicine 124
7.11 Illumina 125
7.12 Genelex 126
7.13 Genomic Health 126
7.14 Myriad 126
7.15 Nodality 127
7.16 OriGene Technologies 130
7.17 Randox 130
7.18 Qiagen 131

8.0 Oncology Biomarker Market Products and Kits 133
8.1 Oncology Companion Diagnostic Tests 133
8.2 23andMe 135
8.3 Affymetrix 139
8.4 Ambry Genetics 140
8.5 Astex Pharmaceuticals 150
8.6 Atossa Genetics 150
8.7 BioMerieux 151
8.8 Celera (Quest Diagnostics) 151
8.9 deCode Genetics 153
8.10 Foundation Medicine 155
8.11 Illumina 157
8.12 Genelex 160
8.13 Genomic Health 160
8.14 Myriad Genetics 163
8.15 Nodility 168
8.16 OriGene 168
8.17 Randox 172
8.18 Qiagen 173
8.19 Roche 177

Single User License of the Report is US $ 3335 for Discount Inquire @ http://www.reportsnreports.com/contacts/discount.aspx?name=291987.

9.0 Market Participant Financial and Business Strategy Analysis 178
9.1 23andMe 178
9.2 Affymetrix 180
9.3 Astex Pharmaceuticals (Otuska Pharamceutical) 189
9.4 Atossa Genetics 192
9.5 BioMerieux 195
9.6 Celera (Quest Diagnostics) 200
9.7 Celldex Therapeutics 206
9.8 deCode Genetics (Amgen) 207
9.9 Foundation Medicine 208
9.10 Illumina 210
9.11 Genelex 213
9.12 Genomic Health 213
9.13 Myriad 214
9.14 Nodality 218
9.15 Qiagen 220

10.0 Objective Business and Strategic Analysis of the Cancer Biomarker Market 225

List of Tables

List of Figures

Other Reports by Kelly Scientific:

Personalized Medicine and Companion Diagnostic Market - A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment - Highlights a number of significant pharmacos and gives details of their operations, products, financials and business strategy.

  • 23andMe
  • Affymetrix
  • Astex Pharmaceuticals
  • Atossa Genetics
  • CuraGen
  • Celera Corporation (Quest Diagnostics)
  • Celldex Therapeutics
  • deCode Genetics (Amgen)
  • Illumina
  • Genelex
  • Myriad
  • Nodality
  • Qiagen

Pharmaceutical Industry in China - Cutting-Edge Analysis of Multinational and Chinese Pharma Companies, Industry Trends, Environment, Regulation, Market Drivers, Restraints, Opportunities & Challenges - Highlights a number of significant Chinese and multinational pharmacos and gives details of their operations, products, financials and business strategy.

  • Amoytop Biotech
  • Active Pharmaceutical Products
  • Beijing Continent Pharmaceuticals
  • FusoGen Pharmaceuticals
  • Shanghai Huaguan Biochip
  • SiBiono GeneTech
  • Abbott
  • AstraZeneca
  • Boehringer Ingelheim
  • Eli Lilly
  • GlaxoSmithKline
  • Johnson & Johnson Medical
  • Merck
  • Novartis
  • Pfizer
  • Roche

About Us:

ReportsnReports.com is an online market research reports library of 350,000+ in-depth studies of over 5000 micro markets. Call +1 888 391 5441 with your research requirements or email the details on sales@reportsandreports.com This e-mail address is being protected from spambots. You need JavaScript enabled to view it and we would be happy to help you find the business intelligence that you need. Not limited to the biotechnology industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, consumer goods, environment, medical devices, healthcare, food and beverages, retail, water, advanced materials and much more.

Media Contact: Ritesh Tiwari, ReportsnReports.com, + 1 888 391 5441, sales@reportsandreports.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE ReportsnReports.com
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Lung Cancer Alliance Congratulates 75 Medical Centers For Moving Swiftly And Responsibly On Lung Cancer Screening
2. VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer
3. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
4. New Veridex Alliance Drives Study Of Circulating Tumor Cells In Men With Metastatic Prostate Cancer
5. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
6. Accuray Launches First Study to Compare CyberKnife® SBRT to Surgery and IMRT for Treatment of Early-Stage Prostate Cancer
7. Elekta, pioneer in treatment of cancer in brain disorders, to Move North America Headquarters to Atlanta
8. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
9. National Jewish Health, the Nations Premier Respiratory Hospital, Announces Lung Cancer Screening Trial Using Blood Test and CT
10. Retrospective Study Suggests that Stereotactic Ablative Radiotherapy (SABR) Can be a Viable Option for Treating Early-Stage Lung Cancer in Operable as well as Inoperable Patients; Phase III Randomized Trial Now Under Way
11. National Patient Advocate Foundation Praises Signing of the Delaware Cancer Treatment Access Act into Law
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... -- Treato , the single largest ... that it has been named a Cool Vendor by ... Sciences, 2016, Stephen Davies , Michael ... life-science- oriented analytics, algorithms and smart machine technology in ... medication ingestion, and analyze unstructured information.   ...
(Date:4/28/2016)... Dr. Vivek Ahuja , ... phen Schmidt Join the Growing ... solutions for life sciences, today announced key new leaders have joined ... to a growing business.  This will bolster the company,s safety business ... joined ArisGlobal in the position of Vice President - Safety. George ...
(Date:4/28/2016)... N.J. , April 28, 2016   Acsis ... today announced that leading IT market research and advisory ... " in the IDC MarketScape: Worldwide Pharmaceutical Track and ... 2016).  The report provides an assessment of the capabilities ... track and trace software market. Logo - ...
Breaking Medicine Technology:
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... ... student loans more flexibility in repaying their loans, more information about their loan ... time when total outstanding student loan debt, including federal and private loans, has ...
(Date:4/29/2016)... ... 29, 2016 , ... Coast Dental Fort Stewart is celebrating its grand opening ... the Exchange Furniture Mall at 112 Vilseck Road in Fort Stewart. There will be ... attendees will have the opportunity to meet general dentists Thomas Richards, DDS, and Josh ...
(Date:4/29/2016)... , ... April 29, 2016 , ... Spine Team Texas, ... is proud to announce one of their physicians has been invited to be a ... (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. R. ...
(Date:4/29/2016)... Kansas City, Missouri (PRWEB) , ... April 29, 2016 , ... ... Unlike traditional crutches which put pressure on the armpits, the M+D Crutch evenly distributes ... less strain on their wrists and hands when using the crutches than with other ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
Breaking Medicine News(10 mins):